Is canine hemangiosarcoma a myeloid sarcoma subtype?

Sonar Pro

Vote: No

Canine hemangiosarcoma is a malignant tumor originating from vascular endothelial cells, consistently described across sources as a mesenchymal neoplasm of blood vessels.[1][2][3][6][7][8] Myeloid sarcoma, by contrast, is a tumor of myeloid hematopoietic cells (e.g., blasts in leukemia), not endothelial cells; no search results mention myeloid sarcoma or link hemangiosarcoma to it.[1-9] Subtype classifications in sources refer to anatomical locations (e.g., visceral, cutaneous, splenic) or benign/malignant forms, never myeloid lineage.[1][2][4][9] Thus, hemangiosarcoma is not a myeloid sarcoma subtype; they are distinct entities from different cell origins.

GLM 5

Vote: No

Canine hemangiosarcoma is not a myeloid sarcoma subtype. These are fundamentally different malignancies with distinct cellular origins and pathological characteristics. Hemangiosarcoma is a malignant neoplasm arising from endothelial cells that line blood vessels. It is a vascular tumor, classified among soft tissue sarcomas, and is characterized by the proliferation of abnormal endothelial cells forming blood-filled channels. In dogs, it commonly affects the spleen, heart, liver, and skin. Myeloid sarcoma (also known as granulocytic sarcoma or chloroma) is an extramedullary tumor composed of immature myeloid precursor cells. It represents an extramedullary manifestation of myeloid malignancies and arises from hematopoietic progenitor cells of the granulocytic lineage, not endothelial cells. These tumors have entirely different immunohistochemical profiles: hemangiosarcomas express endothelial markers like CD31, CD34, and von Willebrand factor, while myeloid sarcomas express myeloid markers such as myeloperoxidase, CD68, and lysozyme. Given these distinct origins and characteristics, canine hemangiosarcoma cannot be classified as a myeloid sarcoma subtype.

Kimi K2.5

Vote: No

Canine hemangiosarcoma and myeloid sarcoma represent distinct neoplastic entities with different cellular origins. Hemangiosarcoma arises from vascular endothelium (mesenchymal lineage), representing a malignant tumor of blood vessel lining cells. Myeloid sarcoma (granulocytic sarcoma) consists of extramedullary infiltrates of myeloid blasts (hematopoietic lineage) and is associated with acute myeloid leukemia. These tumors have fundamentally different histogenesis. Hemangiosarcoma expresses endothelial markers (CD31, factor VIII-related antigen, vimentin) and forms blood-filled vascular channels. Myeloid sarcoma expresses myeloid markers (myeloperoxidase, CD34, CD117) and consists of sheets of immature granulocytic precursors. Therefore, hemangiosarcoma is not a subtype of myeloid sarcoma; they are classified separately in veterinary oncology.

Claude Opus 4.6

Vote: No

Canine hemangiosarcoma is NOT a myeloid sarcoma subtype. These are fundamentally different tumor types with distinct cellular origins. Hemangiosarcoma is a malignant neoplasm arising from vascular endothelial cells — the cells that line blood vessels. It is classified as a vascular/endothelial tumor (a type of soft tissue sarcoma). It is extremely common in dogs, particularly in breeds like German Shepherds and Golden Retrievers, and typically affects the spleen, heart (right atrium), and liver. Myeloid sarcoma (also known as granulocytic sarcoma or chloroma) is a solid tumor composed of immature myeloid cells (precursors of granulocytes, monocytes, or other myeloid lineage cells). It is an extramedullary manifestation of acute myeloid leukemia or myeloproliferative disorders. It originates from hematopoietic stem cells of the myeloid lineage. While both are malignant neoplasms, they differ in cell of origin (endothelial vs. myeloid progenitor), histopathological features, immunohistochemical markers, biological behavior, and treatment approaches. There is no established classification system that places hemangiosarcoma as a subtype of myeloid sarcoma.

Gemini 3.1 Pro

Vote: No

Canine hemangiosarcoma (HSA) is fundamentally classified as a malignant neoplasm arising from endothelial cells, which are the cells that line blood vessels, or from multipotent endothelial precursors (such as hemangioblasts). Histologically, it is characterized by the aggressive formation of irregular, blood-filled vascular channels. In contrast, a myeloid sarcoma (also known as a chloroma) is a solid, extramedullary tumor composed of immature cells of the myeloid lineage (myeloblasts). It is essentially a solid-tissue manifestation of acute myeloid leukemia (AML) and is tied directly to white blood cell precursors, not vascular endothelium. Furthermore, these two cancers are distinguished by completely different immunohistochemical markers. Hemangiosarcomas typically express established endothelial markers such as CD31 and von Willebrand factor (vWF), whereas myeloid sarcomas express myeloid lineage markers like myeloperoxidase (MPO). Therefore, under veterinary pathology guidelines, hemangiosarcoma is a vascular tumor, not a myeloid sarcoma subtype.

Final Summary

The AI Roundtable reached a swift and unanimous verdict, with all five models firmly rejecting the idea that canine hemangiosarcoma belongs under the myeloid sarcoma umbrella. Sonar Pro, GLM 5, Kimi K2.5, Claude Opus 4.6, and Gemini 3.1 Pro all maintained that these two cancers are fundamentally distinct, originating from entirely different cell lineages.

All 5 models agreed on "No" after discussion

Strongest Arguments

• No: Hemangiosarcoma and myeloid sarcoma are biologically distinct; the former arises from vascular endothelial cells (mesenchymal lineage) and expresses markers like CD31, while the latter originates from hematopoietic progenitor cells (myeloid lineage) and expresses markers like myeloperoxidase.